The Sickle Cell Association of Uganda is protesting a government decision to phase out chloroquin in the treatment of malaria.
Ruth Nankanja, the chairperson of the Sickle Cell Association of Uganda says phasing out chloroquin would jeopardize the management of malaria amongst sicklers.
The National Drug Authority decided to phase out chloroquin when it was found to have high resistance to Malaria.
Nankanja says that phasing out the drug with out adequate research could increase deaths among sickle cell patients.
Sickle cell patients take 2 chloroquin tablets twice every week, to prevent malaria that is the leading cause of death amongst sicklers.
Dr. Charles Balyejussa a specialist in Sickle Cell Anemia diseases says that Chloroquine is important in management of Malaria in sicklers.
He says there is no evidence to show that the new anti malaria drugs being introduced are as effective as Chloroquine in preventing Malaria amongst sicklers.
//Cue in: iA study was done#.i
Cue out: #. help them to prevent malariai//
Dr. Balyejussa says management of sickles cell in Uganda is very costly yet the health ministry provides, minimal funding to the treatment of the disease.
//Cue in: iThe best treatment for sickle #.
//Cue out: #30000 for treatmenti//
Sickle cell pain episodes occur when there is a lack of oxygen supply to a specific part of the body. The body reacts to the lack of oxygen in the area where the blood vessels are blocked, causing acute pain.